Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Epigenetic Plasticity of Type II Innate Lymphoid Cells in the Lower Gastrointestinal Tract

Sonia J. Laurie, PhD BSc, Danny W. Bruce, PhD, Hemamalini Bommiasamy, PhD, Melodie P Noel, BS, Joseph P. Foster, III, PhD, Ian J. Davis, MD PhD, Samantha G. Pattenden, PhD, Jonathan S Serody, MD

Blood (2019) 134 (Supplement_1): 1921.

https://doi.org/10.1182/blood-2019-126823

Published: 2019

Journal Articles

Fludarabine/Melphalan 100 Conditioning Therapy Followed By Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis

Han-Seung Park, MD, Jung-Hee Lee, MD PhD, Je-Hwan Lee, MD PhD, Eunji Choi, MD, Sun-Hye Ko, MD PhD, Miee Seol, Young-Shin Lee, Young-Ah Kang, Mijin Jeon, Kyoo Hyung Lee, MD PhD

Blood (2017) 130 (Supplement 1): 2033.

https://doi.org/10.1182/blood.V130.Suppl_1.2033.2033

Published: 2017

Journal Articles

Hospital in the Home Delivery of Conditioning Therapy for Allogeneic Haematopoietic Stem Cell Transplantation: A Novel Single Centre Patient Focused Approach

David J M Routledge, MSc, PGCert, MRCP, FRCPath, Salvatore Fiorenza, MBBS,PhDMPH,BSc, Michael Montalto, Melissa Todd, Andrew B M Lim, David Ritchie, MD PhD

Blood (2017) 130 (Supplement 1): 1936.

https://doi.org/10.1182/blood.V130.Suppl_1.1936.1936

Published: 2017

Journal Articles

Randomized Phase II Multi-Center Trial of Busulfan, Etoposide, and Cyclophosphamide Versus Busulfan, Etoposide, and Melphalan As Conditioning Therapy for Autologous Transplantation in Patients with Non-Hodgkin's Lymphoma: A Multicenter Study from Consortium for Improving Survival of Lymphoma (CISL)

Kyoung Ha Kim, Lee Jae Hoon, Mark Lee, Kim Hoon-Gu, Young Rok Do, Yong Park, MD PhD, Sung Yong Oh, MD, Ho-Jin Shin, MD PhD, Won Seog Kim, Sung-Kyu Park, MD, Jong-Ho Won, Jee Hyun Kong, Moo-Rim Park, MD, Je-Jung Lee, Jae-Yong Kwak, Hye Jin Kang, MD PhD, Yeung-Chul Mun

Blood (2016) 128 (22): 3466.

https://doi.org/10.1182/blood.V128.22.3466.3466

Published: 2016

Journal Articles

Mobile Application Vs. Paper Pictorial Blood Assessment Chart to Track Menses in Young Women: A Randomized Cross-over Design

Amanda E. Jacobson, MD, Sara K. Vesely, PhD, Myra Christian-Rancy, Sarah H. O'Brien, MD MSc

Blood (2016) 128 (22): 1006.

https://doi.org/10.1182/blood.V128.22.1006.1006

Published: 2016

Journal Articles

Mechanism and Activity of ILC2 Cells Post Allo-BMT

Danny W Bruce, PhD, Heather E Stefanski, MD PhD, Benjamin G. Vincent, MD, Trisha Dant, BS, Shannon Reisdorf, BS, Hemamalini Bommiasamy, PhD, David Serody, Justin E Wilson, PhD, Karen McKinnon, PhD, Warren D Shlomchik, MD, Paul M. Armistead, MD PhD, Jenny PY Ting, PhD, John T Woosley, MD PhD, Dietmar MW Zaiss, PhD, Bruce R. Blazar, MD, Andrew NJ McKenzie, PhD, James Coghill, MD, Jonathan S. Serody, MD

Blood (2016) 128 (22): 1155.

https://doi.org/10.1182/blood.V128.22.1155.1155

Published: 2016

Journal Articles

Safety and Efficacy of Thiotepa-Based Conditioning Therapy for Allogeneic Transplantation in Acute Myeloid Leukemia - a Survey from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Sandra Eder, MD, Myriam Labopin, MD, Jurgen Finke, MD, Donald W. Bunjes, MD, Attilio Olivieri, MD, Stella Santarone, MD, Alessandro Rambaldi, MD, Lothar Kanz, MD, Giuseppe Messina, MD, Arnon Nagler, MD, Mohamad Mohty

Blood (2014) 124 (21): 3895.

https://doi.org/10.1182/blood.V124.21.3895.3895

Published: 2014

Journal Articles

Long-Term Outcome Of Adolescents and Young Adults (AYA) After Autologous Transplantation For Lymphoma; Single Center Experience With Bu-CY-VP16 Conditioning Therapy

Rabi Hanna, MD, Brian J. Bolwell, MD, Ronald Sobecks, MD, Brad Pohlman, MD, Deepa Jagadeesh, MD, MPH, Hien K. Duong, MD, Brian T. Hill, MD, PhD, Kelly Cherni, RN, Christina Ferraro, RN, Gina Green, RN, Betty K. Hamilton, MD, Lisa Rybicki, MS, Matt Kalaycio, MD

Blood (2013) 122 (21): 4644.

https://doi.org/10.1182/blood.V122.21.4644.4644

Published: 2013

Journal Articles

Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome

Kyoo-Hyung Lee, Je-Hwan Lee, Jung-Hee Lee, Dae-Young Kim, Miee Seol, Young-Shin Lee, Young-Ah Kang, Mijin Jeon, Hyun-Ju Hwang, Ah-Rang Jung, Sung-Han Kim, Sung-Cheol Yun, Ho-Jin Shin

Blood (2011) 118 (9): 2609–2617.

https://doi.org/10.1182/blood-2011-02-339838

Published: 2011

Journal Articles

Prospective Randomized Comparison of Cyclophosphamide Versus Cyclophosphamide Plus Fludarabine In Addition to Anti-Thymocyte Globulin for the Conditioning Therapy In Allogeneic Hematopoietic Cell Transplantation for Bone Marrow Failure Syndrome

Hawk Kim, Jae-Hoo Park, Je-Hwan Lee, Young Don Joo, Won-Sik Lee, Sung-Hwa Bae, MD, Hun-Mo Ryoo, MD, PhD, Myung Soo Hyun, Min Kyung Kim, Dae Young Zang, Hyo Jung Kim, Kyoo Hyung Lee

Blood (2010) 116 (21): 34.

https://doi.org/10.1182/blood.V116.21.34.34

Published: 2010

Journal Articles

Patterns of Symptom Burden in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation.

Loretta A Williams, PhD, RN, Karen O Anderson, PhD, Xin Shelley Wang, MD, MPH, Charles S Cleeland, PhD, Tito R Mendoza, PhD, Gary M Mobley, MA, Jane O Brown, BSN, RN, Sergio Giralt, MD

Blood (2009) 114 (22): 1396.

https://doi.org/10.1182/blood.V114.22.1396.1396

Published: 2009

Journal Articles

Impact of the Intensity of Conditioning Therapy On the Outcomes of Patients Aged 40 to 60 Years with Acute Myeloid Leukemia/Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation.

Murtadha K. Al-Khabori, BSc, MD, FRCPC, Mohamed El-Emary, MD, Gordon Guyatt, Ahmed Galal, John Kuruvilla, Jeffrey H. Lipton, Hans A. Messner, PhD, Vikas Gupta

Blood (2009) 114 (22): 1202.

https://doi.org/10.1182/blood.V114.22.1202.1202

Published: 2009

Journal Articles

Upregulation of XAF1 by 5-Aza-2′-Deoxycytidine Sensitizes Busulfan-Resistant Human CML Cells; Implications for Pretransplant Conditioning Therapy in Myeloid Leukemia

Benigno C. Valdez, PhD, Yang Li, David Murray, PhD, Richard E. Champlin, MD, Borje S. Andersson, MD, PhD

Blood (2008) 112 (11): 5046.

https://doi.org/10.1182/blood.V112.11.5046.5046

Published: 2008

Journal Articles

Unrelated Transplants for Poor Prognosis Adult Acute Lymphoblastic Leukemia: Long-Term Comparative Analysis Based on the Hematopoietic Progenitor Source.

Blood (2008) 112 (11): 969.

https://doi.org/10.1182/blood.V112.11.969.969

Published: 2008

Journal Articles

Recruitment of Donor T Cells to Secondary Lymphoid Tissue Is Enhanced by Conditioning Therapy and Donor T Cells/Marrow

Jonathan Serody, MD, Chris A Wysocki, Tim P Moran

Blood (2008) 112 (11): 3506.

https://doi.org/10.1182/blood.V112.11.3506.3506

Published: 2008

Journal Articles

Intermediate Dose Melphalan, Bortezomib, Thalidomide, Dexametasone (MVTD) Conditioning Therapy and ASCT in Relapsed Multiple Myeloma Patients: A Single Center Experience.

Potito Rosario Scalzulli, MD, Maria Rosa Valvano, SD, Carlo C. Bodenizza, MD, Angelo Michele Carella, MD, Matteo M. Dell’Olio, MD, Antonietta A.P. Falcone, MD, Michele Mario Greco, MD, Antonio A. La Sala, MD, Francesco F.S. Mantuano, MD, Lorella L. Melillo, MD, Emanuela E. Merla, MD, Michele M. Nobile, MD, Sanpaolo G. Sanpaolo, MD, Nicola N. Cascavilla, MD

Blood (2007) 110 (11): 5117.

https://doi.org/10.1182/blood.V110.11.5117.5117

Published: 2007

Journal Articles

Randomized Comparison of 4-Times-Daily Versus Once-Daily Intravenous Busulfan in a Conditioning Therapy for Hematopoietic Cell Transplantation (HCT).

Seong-Gil Ryu, RPh, Je-Hwan Lee, MD, Seong-Jun Choi, MD, Jung-Hee Lee, MD, Young-Shin Lee, RN, Miee Seol, RN, Eun-Hye Hur, MS, Soo Han Lee, MD, Kyun Seop Bae, MD, Gyu Jeong Noh, MD, Moo-Song Lee, MD, SungCheol Yun, PhD, Sang Beom Han, PhD, Kyoo Hyung Lee, MD

Blood (2006) 108 (11): 2938.

https://doi.org/10.1182/blood.V108.11.2938.2938

Published: 2006

Journal Articles

Long-Term Follow-Up of IV Busulfan (Bu) with Fludarabine (Flu) vs IV Bu with Cyclophosphamide (Cy) as Pre (Allogeneic) Transplant Conditioning Therapy for AML/MDS.

Marcos De Lima, X. Wang, P.F. Thall, D. Couriel, R.B. Jones, E.J. Shpall, U. Popat, S. Giralt, M. Korbling, R. Champlin, B.S. Andersson

Blood (2006) 108 (11): 322.

https://doi.org/10.1182/blood.V108.11.322.322

Published: 2006

Journal Articles

Poor Prognosis for Patients after Myelo- and Non-Myeloablative Conditioning Therapy Followed by Allogeneic Peripheral Blood Stem Cell Transplantation Admitted to Intensive Care Unit.

Frank Neumann, Oliver Lobitz, Roland Fenk, Mustafa Kondakci, Thorsten Graef, Ingmar Bruns, Malte Kelm, Ali-Nuri Huenerlituerkoglu, Rainer Haas, Guido Kobbe

Blood (2006) 108 (11): 3678.

https://doi.org/10.1182/blood.V108.11.3678.3678

Published: 2006

Journal Articles

Lymphocyte Count on Day 56 Predicts for Reduced Risk of Infection Related Mortality Following Non-Myeloablative Allogeneic Haematopoietic Stem Cell Transplantation.

Caroline Alvares, MRCPath, Samar Kulkarni, MRCP, Pawel Kaczmarek, PhD, Radovan Saso, PhD, Helena Woods, Joy Brennan, BSc, Clive Horton, PhD, Jennifer Treleaven, FRCPath, Mark Ethell, MRCPath, Claire Dearden, MRCPath, Gareth Morgan, FRCPath, Michael Potter, FRCPath

Blood (2006) 108 (11): 5324.

https://doi.org/10.1182/blood.V108.11.5324.5324

Published: 2006

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Epigenetic Plasticity of Type II Innate Lymphoid Cells in the Lower Gastrointestinal Tract

Fludarabine/Melphalan 100 Conditioning Therapy Followed By Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis

Hospital in the Home Delivery of Conditioning Therapy for Allogeneic Haematopoietic Stem Cell Transplantation: A Novel Single Centre Patient Focused Approach

Randomized Phase II Multi-Center Trial of Busulfan, Etoposide, and Cyclophosphamide Versus Busulfan, Etoposide, and Melphalan As Conditioning Therapy for Autologous Transplantation in Patients with Non-Hodgkin's Lymphoma: A Multicenter Study from Consortium for Improving Survival of Lymphoma (CISL)

Mobile Application Vs. Paper Pictorial Blood Assessment Chart to Track Menses in Young Women: A Randomized Cross-over Design

Mechanism and Activity of ILC2 Cells Post Allo-BMT

Safety and Efficacy of Thiotepa-Based Conditioning Therapy for Allogeneic Transplantation in Acute Myeloid Leukemia - a Survey from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Long-Term Outcome Of Adolescents and Young Adults (AYA) After Autologous Transplantation For Lymphoma; Single Center Experience With Bu-CY-VP16 Conditioning Therapy

Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome

Prospective Randomized Comparison of Cyclophosphamide Versus Cyclophosphamide Plus Fludarabine In Addition to Anti-Thymocyte Globulin for the Conditioning Therapy In Allogeneic Hematopoietic Cell Transplantation for Bone Marrow Failure Syndrome

Patterns of Symptom Burden in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation.

Impact of the Intensity of Conditioning Therapy On the Outcomes of Patients Aged 40 to 60 Years with Acute Myeloid Leukemia/Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation.

Upregulation of XAF1 by 5-Aza-2′-Deoxycytidine Sensitizes Busulfan-Resistant Human CML Cells; Implications for Pretransplant Conditioning Therapy in Myeloid Leukemia

Unrelated Transplants for Poor Prognosis Adult Acute Lymphoblastic Leukemia: Long-Term Comparative Analysis Based on the Hematopoietic Progenitor Source.

Recruitment of Donor T Cells to Secondary Lymphoid Tissue Is Enhanced by Conditioning Therapy and Donor T Cells/Marrow

Intermediate Dose Melphalan, Bortezomib, Thalidomide, Dexametasone (MVTD) Conditioning Therapy and ASCT in Relapsed Multiple Myeloma Patients: A Single Center Experience.

Randomized Comparison of 4-Times-Daily Versus Once-Daily Intravenous Busulfan in a Conditioning Therapy for Hematopoietic Cell Transplantation (HCT).

Long-Term Follow-Up of IV Busulfan (Bu) with Fludarabine (Flu) vs IV Bu with Cyclophosphamide (Cy) as Pre (Allogeneic) Transplant Conditioning Therapy for AML/MDS.

Poor Prognosis for Patients after Myelo- and Non-Myeloablative Conditioning Therapy Followed by Allogeneic Peripheral Blood Stem Cell Transplantation Admitted to Intensive Care Unit.

Lymphocyte Count on Day 56 Predicts for Reduced Risk of Infection Related Mortality Following Non-Myeloablative Allogeneic Haematopoietic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only